|
One-way ANOVA (p)
|
Post hoc 1–2 (p)
|
Post hoc 1–3 (p)
|
Post hoc 2–3 (p)
|
95% CI 1–2
|
95% CI 1–3
|
95% CI 2–3
|
---|
Baseline parameters
|
IL 6 d1
|
0.286
|
0.999
|
0.374
|
0.304
|
− 254–263
|
− 458–129
|
− 443–105
|
CRP d1
|
0.805
|
0.861
|
0.813
|
0.985
|
− 8.08–5.19
|
− 9.47–5.62
|
− 7.52–6.54
|
Creatinine d1
|
< 0.001
|
0.702
|
< 0.001
|
< 0.001
|
− 0.7–0.4
|
− 1.7 to − 0.5
|
− 1.5 to − 0.3
|
Urea d1
|
0.001
|
0.260
|
0.001
|
0.021
|
− 35–7
|
− 64 to − 16
|
− 48 to − 3
|
CLCR d1
|
< 0.001
|
0.002
|
< 0.001
|
0.007
|
17–88
|
61–138
|
11–83
|
RRT d1
|
0.066
|
0.832
|
0.066
|
0.146
|
− 0.3–0.2
|
− 0.6–0.02
|
− 0.5–0.06
|
Bilirubin d1
|
0.499
|
0.947
|
0.677
|
0.475
|
− 1.5–1.9
|
− 2.6–1.2
|
− 2.6–0.9
|
ALT d1
|
0.723
|
0.781
|
0.754
|
0.988
|
− 174–306
|
− 196–361
|
− 249–281
|
AST d1
|
0.728
|
0.938
|
0.900
|
0.706
|
− 308–230
|
− 250–361
|
− 191–379
|
GGT d1
|
0.283
|
0.931
|
0.482
|
0.261
|
− 108–145
|
− 213–75
|
− 222–46
|
APACHE II d1
|
0.026
|
0.989
|
0.061
|
0.03
|
− 5.0–5.6
|
− 11.8–0.2
|
− 11.7 to − 0.5
|
SOFA d1
|
0.133
|
0.123
|
0.338
|
0.703
|
− 4.3–1.1
|
− 5.7–0.5
|
− 3.8–1.9
|
Age
|
0.010
|
0.204
|
0.007
|
0.183
|
− 17.1–2.8
|
− 26.3 to − 3.6
|
− 18.4–2.7
|
BMI
|
0.845
|
1.00
|
0.874
|
1.00
|
− 11.0–11.0
|
− 10.0–15.1
|
− 9.1–14.3
|
Sex
|
0.78
|
0.82
|
0.806
|
0.994
|
− 0.5–0.3
|
− 0.6–0.3
|
− 0.4–0.4
|
Delta parameters
|
ΔIL-6 (d1–d3)
|
0.236
|
0.959
|
0.255
|
0.319
|
− 291–231
|
− 494–100
|
− 444–109
|
ΔCRP (d1–d3)
|
0.015
|
0.033
|
0.026
|
0.903
|
− 11.2 to − 0.4
|
− 12.9 to − 0.67
|
− 6.7–4.7
|
ΔCreatinine (d1–d5)
|
0.253
|
0.900
|
0.236
|
0.37
|
− 0.4–0.6
|
− 0.2–1.1
|
− 0.3–1.0
|
ΔUrea (d1–d5)
|
0.327
|
0.79
|
0.657
|
0.298
|
− 34–20
|
− 21–45
|
− 12–50
|
ΔCLCR (d1–d5)
|
0.419
|
0.398
|
0.891
|
0.763
|
− 22–73
|
− 45–66
|
− 67–37
|
ΔBilirubin (d1–d5)
|
0.946
|
0.957
|
1.00
|
0.961
|
− 1.3–1.7
|
− 1.7–1.7
|
− 1.7–1.4
|
ΔALT (d1–d5)
|
0.526
|
0.632
|
0.553
|
0.978
|
− 174–306
|
− 196–361
|
− 249–281
|
ΔAST (d1–d5)
|
0.781
|
0.999
|
0.841
|
0.782
|
− 242–232
|
− 206–330
|
− 175–310
|
ΔGGT (d1–d5)
|
0.765
|
0.951
|
0.750
|
0.869
|
− 190–244
|
− 171–319
|
− 175–268
|
ΔAPACHE II (d1–d5)
|
0.227
|
0.358
|
0.231
|
0.887
|
− 1.3–4.7
|
− 1.0–5.6
|
− 2.4–3.6
|
ΔSOFA (d1–d5)
|
0.215
|
0.197
|
0.766
|
0.597
|
− 1.7–10.3
|
− 4.8–8.6
|
− 10.3–1.7
|
Neurological disorder d5
|
0.43
|
0.473
|
0.518
|
0.997
|
− 0.6–0.2
|
− 0.6–0.2
|
− 0.4–0.4
|
In-hospital mortality
|
0.002
|
0.728
|
0.001
|
0.017
|
− 0.2 – 0.4
|
− 0.7 to − 0.06
|
− 0.8 to − 0.2
|
Estimated mortality
|
0.123
|
0.996
|
0.198
|
0.135
|
− 0.1 – 0.1
|
− 0.3–0.05
|
− 0.3–0.03
|
- ANOVA analysis of variance, CI confidence interval, IL-6 interleukin-6, CRP C-reactive protein, ALT serum alanine aminotransferase, AST serum aspartate aminotransferase, GGT glutamine glutamyl transferase, CLCR creatinine clearance, RRT renal replacement therapy, d day, BMI body mass index